XML 79 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE N – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. In the first quarter of 2022, we reorganized our business structure into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. We have revised prior periods to conform to current year presentation:
Year Ended December 31,
202220212020
BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$1,341 $880 $2,221 $1,222 $919 $2,141 1,000 $780 $1,780 
Urology1,257 516 1,773 1,120 463 1,583 918 368 1,286 
Neuromodulation715 202 917 713 196 909 610 151 761 
MedSurg3,312 1,599 4,911 3,055 1,578 4,633 2,528 1,299 3,827 
Interventional Cardiology Therapies744 1,485 2,228 778 1,431 2,209 728 1,247 1,975 
Watchman915 103 1,019 729 100 829 253 71 324 
Cardiac Rhythm Management1,337 763 2,100 1,214 805 2,019 992 712 1,704 
Electrophysiology275 310 585 128 237 365 118 169 287 
Cardiology3,271 2,662 5,932 2,850 2,572 5,422 2,091 2,199 4,290 
Peripheral Interventions1,048 850 1,899 996 824 1,820 888 689 1,577 
Cardiovascular4,319 3,512 7,831 3,846 3,396 7,242 2,979 2,888 5,866 
Other1
— — (60)10 4 13 193 27 219 
Total Net Sales$7,632 $5,111 $12,682 $6,911 $4,978 $11,888 $5,701 $4,212 $9,913 
(1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Specialty Pharmaceuticals net sales were substantially U.S. based.

Refer to Note M – Segment Reporting for information on our reportable segments.

Year Ended December 31,
Geographic Regions202220212020
U.S.$7,632 $6,901 $5,508 
Europe, Middle East and Africa2,526 2,518 2,097 
Asia-Pacific2,116 2,070 1,781 
Latin America and Canada469 386 307 
Other1
(60)13 219 
Total Net Sales$12,682 $11,888 $9,913 
Emerging Markets(2)
$1,715 $1,429 $1,138 
(2)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye and Vietnam. We have revised prior period amounts to conform to the current year's presentation.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying consolidated balance sheets. Our deferred revenue balance was $509 million as of December 31, 2022 and $484 million as of December 31, 2021. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the
average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $156 million in 2022 that was included in the above contract liability balance as of December 31, 2021. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period.

In 2020, we recorded $179 million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX™ Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and subsequently recognized revenue for consigned units as they were consumed.

Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.